Novo Nordisks stock has tumbled from record highs after slashing its 2025 outlook, as fierce competition, leadership changes, ...

Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...

Novo Nordisk has plummeted back to Earth after a stunning rise driven by Ozempic and Wegovy. Can the storied Danish pharma ...

More than one in five UK adults tried to access weight-loss medications in the past year alone, according to a survey by the ...

Here are five oral obesity candidates that, according to Mizuho’s Graig Suvannavejh, could change the weight loss game.

Novo Nordisk remains the GLP-1 leader with over 65% market share. Read an in-depth BVO stock analysis and why we rate it as a ...

Shares of Novo Nordisk (NYSE:NVO), traded in Copenhagen, rose over 5% on Friday, extending gains from the previous session.

Novo Nordisk A/S climbed 3.72% during Friday's pre-market trading session, after rival Eli Lilly 's Phase 3 ATTAIN-1 trial for obesity drug, orforglipron trailed the Danish drug giant's semaglutide.

Lilly executives have touted the once-daily pill, known as orforglipron, as a cheaper alternative to recently-popular obesity ...